Simvastatin, a cholesterol-lowering agent, in combination with the EGFR inhibitor cetuximab, significantly suppresses tumor growth and extends survival, suggesting that inhibiting YAP activity is a key mechanism enhancing CRC treatment outcome (53). This evidence concerns the gene YAP1 and neoplasm.